Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).docVIP

下载本文档

6
0
约2.06万字
约 5页
2017-05-16 发布于上海
举报

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).doc

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)

Boschetal.AIDSResearchandTherapy2010,7:30 /content/7/1/30 RESEARCH OpenAccess ContinuingoraddingIL-2inpatientstreatedwith antiretroviraltherapy(ACTGProtocolA5051,a rollovertrialofACTGProtocolA328) RonaldJBosch1*,RichardBPollard2,AlanLanday3,EvgeniaAga1,LawrenceFox4,RonaldMitsuyasu5 Abstract Background:EffectiveantiretroviraltherapyreducesHIV-1RNAlevels,improvesCD4T-cellcounts,andlowersthe riskofopportunisticinfectionsandmalignancies.Interleukin-2(IL-2)hasbeenshowntoincreaseCD4T-cell numbersmainlybyexpandingCD4cellsandbyprolongingtheirhalf-lives.HIV-infectedpatientspreviously enrolledintoA328

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).docVIP